Yale University, Yale Cancer Center

New Haven, CT


Yale Cancer Center combines a tradition of innovative cancer treatment and quality care for our patients. A National Cancer Institute (NCI) designated comprehensive cancer center for over 43 years, Yale Cancer Center is one of only 49 Centers in the nation. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

 Pediatric Hematology and Oncology faculty treats childhood cancer and blood disorders, providing the best patient care, developing and implementing the latest advances in diagnosis and treatment, and educating patients, families and future Pediatric Hematologists/Oncologists.

Contact information


35 Park Street
New Haven, CT 06519 


Phone: (203) 785-4640



Principal Investigator

Asher Marks, MD

Pediatric Neuroncologist
Asher Marks, MD is the Director of Pediatric Neuro-Oncology at the Yale University School of Medicine. He is a clinician researcher and educator with a particular interest in the development of early phase trials for the treatment of aggressive pediatric brain tumors. Dr. Marks received his medical degree from Temple University and went on to complete a pediatric residency, pediatric hematology/oncology fellowship, and pediatric neuro-oncology fellowship at Children’s National Medical Center. He is the study chair of PNOC 017 and is an active and vocal advocate for the adolescent and young adult (AYA) cancer population.
Co-Principal Investigator

Ranjit Bindra, MD PhD

Pediatric Radioncolgoist
Ranjit Bindra, MD PhD is a physician-scientist and biotech entrepreneur at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumors, and he is a member of the Yale radiosurgery team, with expertise in treating brain metastases and benign tumors such as arteriovenous malformations. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University, and both his MD and PhD from the Yale School of Medicine. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center. Dr. Bindra is the study co-chair of PNOC 017 and his group led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors.